Alnylam Pharmaceuticals Balance Sheet Analysis

Assets, liabilities, and stockholders equity in billions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Alnylam Pharmaceuticals, Inc. (ALNY) - Annual data in billions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Current Assets
Cash and Cash Equivalents0.972.440.870.821.871.541.08
Short-Term Investments1.731.631.331.621.380.000.00
Cash & Short-Term Investments2.692.442.192.441.871.541.08
Accounts Receivable0.410.330.240.200.600.040.02
Inventory0.080.090.130.090.080.060.02
Other Current Assets0.120.130.130.090.060.000.00
Total Current Assets3.302.982.692.812.611.721.20
Non-Current Assets
Property, Plant & Equipment (Net)0.690.730.740.730.710.650.32
Other Non-Current Assets0.130.110.120.100.090.030.05
Total Non-Current Assets0.940.850.850.830.790.680.37
Total Assets4.243.833.553.643.412.401.57
Current Liabilities
Accounts Payable0.090.770.100.070.410.250.14
Short-Term Debt0.150.050.040.040.010.000.00
Current Portion of Long-Term Debt0.110.050.040.040.010.000.00
Accrued Liabilities0.670.650.410.370.300.000.00
Deferred Revenue0.060.100.040.150.130.000.00
Other Current Liabilities0.891.380.040.020.100.070.00
Total Current Liabilities1.190.970.770.700.570.350.18
Non-Current Liabilities
Long-Term Debt2.591.261.021.830.480.280.03
Other Non-Current Liabilities0.400.311.460.100.050.010.00
Total Non-Current Liabilities2.991.762.942.361.820.600.09
Total Liabilities4.174.053.703.062.390.960.27
Stockholders' Equity
Common Stock0.000.000.000.000.000.000.00
Retained Earnings-7.29-7.03-6.57-5.44-4.63-3.76-2.84
Accumulated Other Comprehensive Income-0.03-0.02-0.04-0.03-0.04-0.04-0.03
Additional Paid-in Capital7.396.816.456.065.645.204.18
Shares Outstanding0.130.130.120.120.000.000.00
Total Stockholders' Equity0.07-0.22-0.160.591.021.441.30
Total Liabilities & Equity4.243.833.553.643.412.401.57